The Filing Desk

IM Cannabis vs Nektar Therapeutics

IM Cannabis IMCC · Nektar Therapeutics NKTR · Pharmaceuticals

IM Cannabis reported revenue of C$55 million in fiscal 2025, and Nektar Therapeutics $55 million in fiscal 2025, in different currencies. IM Cannabis' revenue grew 1.3% in its latest year, and Nektar Therapeutics' fell 43.9%. IM Cannabis had an operating margin of -21.2%, against -253.7% at Nektar Therapeutics. Free cash flow was C$5 million at IM Cannabis and −$209 million at Nektar Therapeutics.

Side by side

IM CannabisNektar Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
RevenueC$55M$55M
Revenue growth1.3%−43.9%
Revenue growth a year, last 5 years28.0%−18.4%
Gross margin17.7%100.0%
Operating margin−21.2%−253.7%
Net margin−20.7%−297.1%
Free cash flowC$5M−$209M
Free cash flow margin8.6%−377.8%
Return on capital−64.9%—
Net debt to EBITDA——
Dividends and buybacksC$0M$0M
Change in diluted share count—23.1%
Last close$0.47$32.54
P/E at the last close——
Insider trades, last 12 months—sold $2.5 million
Piotroski F-score—2 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
IM CannabisNektar Therapeutics
Operating margin
Percent of revenue
IM CannabisNektar Therapeutics
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
IM CannabisNektar Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the IM Cannabis and Nektar Therapeutics pages.